Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.

Chi BH, Mwango A, Giganti M, Mulenga LB, Tambatamba-Chapula B, Reid SE, Bolton-Moore C, Chintu N, Mulenga PL, Stringer EM, Sheneberger R, Mwaba P, Stringer JS.

J Acquir Immune Defic Syndr. 2010 May 1;54(1):63-70. doi: 10.1097/QAI.0b013e3181c6c65c.

2.

Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia.

Chi BH, Mwango A, Giganti MJ, Sikazwe I, Moyo C, Schuttner L, Mulenga LB, Bolton-Moore C, Chintu NT, Sheneberger R, Stringer EM, Stringer JS.

J Acquir Immune Defic Syndr. 2011 Dec 15;58(5):475-81. doi: 10.1097/QAI.0b013e31823058a3.

3.

Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir.

Njuguna C, Orrell C, Kaplan R, Bekker LG, Wood R, Lawn SD.

PLoS One. 2013 May 22;8(5):e63596. doi: 10.1371/journal.pone.0063596. Print 2013.

4.

Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.

Velen K, Lewis JJ, Charalambous S, Grant AD, Churchyard GJ, Hoffmann CJ.

PLoS One. 2013 May 14;8(5):e64459. doi: 10.1371/journal.pone.0064459. Print 2013.

5.

Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.

Mulenga L, Musonda P, Mwango A, Vinikoor MJ, Davies MA, Mweemba A, Calmy A, Stringer JS, Keiser O, Chi BH, Wandeler G; IeDEA-Southern Africa.

Clin Infect Dis. 2014 May;58(10):1473-80. doi: 10.1093/cid/ciu117. Epub 2014 Feb 27.

6.

A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.

Saez-Llorens X, Castaño E, Rathore M, Church J, Deville J, Gaur A, Estripeaut D, White K, Arterburn S, Enejosa JV, Cheng AK, Chuck SL, Rhee MS.

Pediatr Infect Dis J. 2015 Apr;34(4):376-82. doi: 10.1097/INF.0000000000000289.

PMID:
25760565
7.

Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.

Wandeler G, Keiser O, Mulenga L, Hoffmann CJ, Wood R, Chaweza T, Brennan A, Prozesky H, Garone D, Giddy J, Chimbetete C, Boulle A, Egger M; IeDEA Southern Africa Collaboration.

J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):41-8.

8.

Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.

Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G.

Antivir Ther. 2006;11(2):233-43.

PMID:
16640104
9.

The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.

Winston A, McAllister J, Amin J, Cooper DA, Carr A.

HIV Med. 2005 May;6(3):191-7.

10.

High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.

Skhosana L, Steegen K, Bronze M, Lukhwareni A, Letsoalo E, Papathanasopoulos MA, Carmona SC, Stevens WS.

PLoS One. 2015 Feb 6;10(2):e0118145. doi: 10.1371/journal.pone.0118145. eCollection 2015.

11.

Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa.

Wandeler G, Gerber F, Rohr J, Chi BH, Orrell C, Chimbetete C, Prozesky H, Boulle A, Hoffmann CJ, Gsponer T, Fox MP, Zwahlen M, Egger M; IeDEA Southern Africa.

Antivir Ther. 2014;19(5):521-5. doi: 10.3851/IMP2710. Epub 2013 Dec 3.

12.

Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.

Tan DH, Chan K, Raboud J, Cooper C, Montaner JS, Walmsley S, Hogg RS, Klein MB, Machouf N, Rourke SB, Tsoukas C, Loutfy MR; CANOC Collaboration.

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):38-46. doi: 10.1097/QAI.0b013e3182282cfc.

PMID:
21709570
13.

Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.

Ribera E, Larrousse M, Curran A, Negredo E, Clotet B, Estrada V, Sanz J, Berenguer J, Rubio R, Pulido F, Ferrer P, Alvarez ML, Arterburn S, Martínez E.

HIV Med. 2013 Jul;14(6):327-36. doi: 10.1111/hiv.12011. Epub 2013 Jan 9.

14.

Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir.

Brennan AT, Shearer K, Maskew M, Long L, Sanne I, Fox MP.

Trop Med Int Health. 2014 May;19(5):490-8. doi: 10.1111/tmi.12285. Epub 2014 Mar 3.

15.

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.

von Wyl V, Cambiano V, Jordan MR, Bertagnolio S, Miners A, Pillay D, Lundgren J, Phillips AN.

PLoS One. 2012;7(8):e42834. doi: 10.1371/journal.pone.0042834. Epub 2012 Aug 8.

16.

The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy.

Madruga JR, Cassetti I, Suleiman JM, Etzel A, Zhong L, Holmes CB, Cheng AK, Enejosa J; Study 903E Team.

HIV Clin Trials. 2007 Nov-Dec;8(6):381-90.

PMID:
18042503
17.

Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho.

Jouquet G, Bygrave H, Kranzer K, Ford N, Gadot L, Lee J, Hilderbrand K, Goemaere E, Vlahakis N, Trivino L, Makakole L, Cleary S.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):e68-74. doi: 10.1097/QAI.0b013e31822a9f8d.

PMID:
21765366
18.

Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa.

Brennan AT, Maskew M, Ive P, Shearer K, Long L, Sanne I, Fox MP.

J Int AIDS Soc. 2013 Nov 19;16:18794. doi: 10.7448/IAS.16.1.18794.

19.

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.

Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, Chen SS, McColl D, Enejosa J, Toole JJ, Cheng AK.

J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):535-40.

PMID:
17057609
20.

Supplemental Content

Support Center